Neuropharmacology of N,N-dimethyltryptamine

Overview

Journal Brain Res Bull

Specialty Neurology

Date 2016 Apr 30

PMID 27126737

Citations 69

Authors

Theresa M Carbonaro

Michael B Gatch

Affiliations

Soon will be listed here.

Abstract

N,N-dimethyltryptamine (DMT) is an indole alkaloid widely found in plants and animals. It is best known for producing brief and intense psychedelic effects when ingested. Increasing evidence suggests that endogenous DMT plays important roles for a number of processes in the periphery and central nervous system, and may act as a neurotransmitter. This paper reviews the current literature of both the recreational use of DMT and its potential roles as an endogenous neurotransmitter. Pharmacokinetics, mechanisms of action in the periphery and central nervous system, clinical uses and adverse effects are also reviewed. DMT appears to have limited neurotoxicity and other adverse effects except for intense cardiovascular effects when administered intravenously in large doses. Because of its role in nervous system signaling, DMT may be a useful experimental tool in exploring how the brain works, and may also be a useful clinical tool for treatment of anxiety and psychosis.

Citing Articles

Ayahuasca partially preserves striatal integrity in juvenile non-human primates exposed to chronic stress: evidence from stereological evaluation.

de Lira-Bandeira W, de Mendonca Batista L, de Medeiros Bandeira A, de Gois Morais P, Pereira L, de Meiroz Grilo M Front Neuroanat. 2025; 19:1457557.

PMID: 40060188 PMC: 11886963. DOI: 10.3389/fnana.2025.1457557.

Phenethylaminylation: Preliminary Evidence for the Covalent Transamidation of Psychedelic Phenethylamines to Glial Proteins using 3,5-Dimethoxy-4-(2-Propynyloxy)-Phenethylamine as a Model Compound.

Rangan R, Petty R, Acharya S, Emmitte K, do Valle R, Lam C bioRxiv. 2025; .

PMID: 40027829 PMC: 11870397. DOI: 10.1101/2025.02.13.638188.

Unveiling the Complexities of Medications, Substance Abuse, and Plants for Recreational and Narcotic Purposes: An In-Depth Analysis.

Predescu I, Jijie A, Patrascu D, Pasc A, Piros E, Trandafirescu C Pharmacy (Basel). 2025; 13(1).

PMID: 39998006 PMC: 11859396. DOI: 10.3390/pharmacy13010007.

Blood-brain-barrier-crossing lipid nanoparticles for mRNA delivery to the central nervous system.

Wang C, Xue Y, Markovic T, Li H, Wang S, Zhong Y Nat Mater. 2025; .

PMID: 39962245 DOI: 10.1038/s41563-024-02114-5.

Clinical Pharmacokinetics of N,N-Dimethyltryptamine (DMT): A Systematic Review and Post-hoc Analysis.

van der Heijden K, Otto M, Schoones J, van Esdonk M, Borghans L, van Hasselt J Clin Pharmacokinet. 2025; 64(2):215-227.

PMID: 39838235 PMC: 11782443. DOI: 10.1007/s40262-024-01450-8.

References

Griffiths R, Richards W, Johnson M, McCann U, Jesse R . Mystical-type experiences occasioned by psilocybin mediate the attribution of personal meaning and spiritual significance 14 months later. J Psychopharmacol. 2008; 22(6):621-32. PMC: 3050654. DOI: 10.1177/0269881108094300. View

Sitaram B, Lockett L, Talomsin R, Blackman G, McLeod W . In vivo metabolism of 5-methoxy-N,N-dimethyltryptamine and N,N-dimethyltryptamine in the rat. Biochem Pharmacol. 1987; 36(9):1509-12. DOI: 10.1016/0006-2952(87)90118-3. View

Stoff D, Moja E, Gillin J, Wyatt R . Dose response and time course effects of N,N-dimethyltryptamine on disruption of rat shuttlebox avoidance. Biol Psychiatry. 1977; 12(3):339-46. View

Tupper K . The globalization of ayahuasca: harm reduction or benefit maximization?. Int J Drug Policy. 2008; 19(4):297-303. DOI: 10.1016/j.drugpo.2006.11.001. View

Checkley S, Murray R, Oon M, Rodnight R, Birley J . A longitudinal study of urinary excretion of N,N,-dimethyltryptamine in psychotic patients. Br J Psychiatry. 1980; 137:236-9. DOI: 10.1192/bjp.137.3.236. View

Conn P, Sanders-Bush E . Selective 5HT-2 antagonists inhibit serotonin stimulated phosphatidylinositol metabolism in cerebral cortex. Neuropharmacology. 1984; 23(8):993-6. DOI: 10.1016/0028-3908(84)90017-0. View

Gardner D, Riet-Correa F, Lemos D, Welch K, Pfister J, Panter K . Teratogenic effects of Mimosa tenuiflora in a rat model and possible role of N-methyl- and N,N-dimethyltryptamine. J Agric Food Chem. 2014; 62(30):7398-401. DOI: 10.1021/jf5005176. View

Lowe L, Peterson B, Couper F . A Case Review of the First Analytically Confirmed 25I-NBOMe-Related Death in Washington State. J Anal Toxicol. 2015; 39(8):668-71. DOI: 10.1093/jat/bkv092. View

Dos Santos R, Valle M, Bouso J, Nomdedeu J, Rodriguez-Espinosa J, McIlhenny E . Autonomic, neuroendocrine, and immunological effects of ayahuasca: a comparative study with d-amphetamine. J Clin Psychopharmacol. 2011; 31(6):717-26. DOI: 10.1097/JCP.0b013e31823607f6. View

10.

Saavedra J, Axelrod J . Psychotomimetic N-methylated tryptamines: formation in brain in vivo and in vitro. Science. 1972; 175(4028):1365-6. DOI: 10.1126/science.175.4028.1365. View

11.

Barbanoj M, Riba J, Clos S, Gimenez S, Grasa E, Romero S . Daytime Ayahuasca administration modulates REM and slow-wave sleep in healthy volunteers. Psychopharmacology (Berl). 2007; 196(2):315-26. DOI: 10.1007/s00213-007-0963-0. View

12.

Smith T, Weissbach H, UDENFRIEND S . Studies on the mechanism of action of monoamine oxidase: metabolism of N,N-dimethyltryptamine and N,N-dimethyltryptamine-N-oxide. Biochemistry. 1962; 1:137-43. DOI: 10.1021/bi00907a021. View

13.

Keiser M, Setola V, Irwin J, Laggner C, Abbas A, Hufeisen S . Predicting new molecular targets for known drugs. Nature. 2009; 462(7270):175-81. PMC: 2784146. DOI: 10.1038/nature08506. View

14.

Glennon R, Young R, Jacyno J, Slusher M, ROSECRANS J . DOM-stimulus generalization to LSD and other hallucinogenic indolealkylamines. Eur J Pharmacol. 1983; 86(3-4):453-9. DOI: 10.1016/0014-2999(83)90196-6. View

15.

Hungen K, Roberts S, Hill D . Interactions between lysergic acid diethylamide and dopamine-sensitive adenylate cyclase systems in rat brain. Brain Res. 1975; 94(1):57-66. DOI: 10.1016/0006-8993(75)90876-8. View

16.

Trulson M, Ross C, Jacobs B . Lack of tolerance to the depression of raphe unit activity by lysergic acid diethylamide. Neuropharmacology. 1977; 16(11):771-4. DOI: 10.1016/0028-3908(77)90135-6. View

17.

Lyon R, Titeler M, Seggel M, Glennon R . Indolealkylamine analogs share 5-HT2 binding characteristics with phenylalkylamine hallucinogens. Eur J Pharmacol. 1988; 145(3):291-7. DOI: 10.1016/0014-2999(88)90432-3. View

18.

ANDEN N, CORRODI H, Fuxe K . Hallucinogenic drugs of the indolealkylamine type and central monoamine neurons. J Pharmacol Exp Ther. 1971; 179(2):236-49. View

19.

Ahern G . 5-HT and the immune system. Curr Opin Pharmacol. 2011; 11(1):29-33. PMC: 3144148. DOI: 10.1016/j.coph.2011.02.004. View

20.

Carbonaro T, Forster M, Gatch M . Discriminative stimulus effects of N,N-diisopropyltryptamine. Psychopharmacology (Berl). 2012; 226(2):241-6. PMC: 3577941. DOI: 10.1007/s00213-012-2891-x. View